Advances in the Management of Moderate-to-Severe Atopic Dermatitis

Guest: Terry Faleye, MPAS, PA-C
Guest: Jonathan I. Silverberg, MD, PhD, MPH

Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.

Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD

Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.

Host: Jeffrey S. Weber, MD, PhD
Host: Ryan Sullivan, MD
Host: Omid Hamid, MD

Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Omid Hamid, MD
Host: Sapna Patel, MD
Host: Ryan Sullivan, MD
Host: Jeffrey S. Weber, MD, PhD

Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Jason J. Luke, MD, FACP
Host: Ryan Sullivan, MD
Host: Omid Hamid, MD

Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Ryan Sullivan, MD
Host: Omid Hamid, MD

Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Sapna Patel, MD
Host: Jason J. Luke, MD, FACP

Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic disease remain low. With two mechanistically different immune checkpoint inhibitor combinations available, it is critical that clinicians be able to differentiate among currently approved regimens to inform frontline treatment selection in different patient populations. The crucial question revolves around which target, anti-CTLA-4 versus anti-LAG3, provides the greatest benefit in metastatic melanoma when combined with a PD-1 inhibitor.

Report with a jury of your peers to debate the optimal frontline treatment approach for a patient with unresectable stage IV BRAF-wild type melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this vulnerable patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Sapna Patel, MD
Host: Omid Hamid, MD
Host: Jason J. Luke, MD, FACP

Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic disease remain low. With two mechanistically different immune checkpoint inhibitor combinations available, it is critical that clinicians be able to differentiate among currently approved regimens to inform frontline treatment selection in different patient populations. The crucial question revolves around which target, anti-CTLA-4 versus anti-LAG3, provides the greatest benefit in metastatic melanoma when combined with a PD-1 inhibitor.

Report with a jury of your peers to debate the optimal frontline treatment approach for a patient with unresectable stage IV BRAF-wild type melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this vulnerable patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Jason J. Luke, MD, FACP
Host: Ryan Sullivan, MD
Host: Sapna Patel, MD

Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic disease remain low. With two mechanistically different immune checkpoint inhibitor combinations available, it is critical that clinicians be able to differentiate among currently approved regimens to inform frontline treatment selection in different patient populations. The crucial question revolves around which target, anti-CTLA-4 versus anti-LAG3, provides the greatest benefit in metastatic melanoma when combined with a PD-1 inhibitor.

Report with a jury of your peers to debate the optimal frontline treatment approach for a patient with unresectable stage IV BRAF-wild type melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this vulnerable patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Sapna Patel, MD
Host: Jason J. Luke, MD, FACP

Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic disease remain low. With two mechanistically different immune checkpoint inhibitor combinations available, it is critical that clinicians be able to differentiate among currently approved regimens to inform frontline treatment selection in different patient populations. The crucial question revolves around which target, anti-CTLA-4 versus anti-LAG3, provides the greatest benefit in metastatic melanoma when combined with a PD-1 inhibitor.

Report with a jury of your peers to debate the optimal frontline treatment approach for a patient with unresectable stage IV BRAF-wild type melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this vulnerable patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!